Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.53 CNY | +3.43% |
|
+0.27% | -37.15% |
11:00am | Biocytogen Pharmaceuticals Enters License Contract with Cancer Drug Firm | MT |
07-16 | SOTIO Biotech Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.15% | 385M | |
+25.83% | 47.96B | |
+44.70% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Enters License Contract with Cancer Drug Firm